复旦大学附属中山医院胰腺外科是中国最早开展胰十二指肠切除手术的大型医疗中心之一。目前形成特色鲜明的 “以手术为中心的胰腺肿瘤综合诊治模式”，也打造了“开放-腹腔镜-机器人”的全手术体系。2005年率先组织了国内跨区域联合的多学科诊疗，2023年建成全国首家“胆胰肿瘤肝转移多学科联合门诊”。是中华医学会外科学分会胰腺外科学组的副组长单位，也是教育部重点学科和国家“211”工程重点科室。 2015年，中山胰腺外科集中全院优势学科，建成集医教研为一体且多科室联动的“中山胰腺肿瘤中心”，并于2022年获批成为国家癌症中心首批“胰腺癌临床质控中心”，2024年牵头主持了上海市胰腺手术的质量控制检查。科室先后承担包括国家自然科学基金重大仪器项目、科技部重大专项在内的国家级课题50余项；牵头或参与国内外多中心临床研究超过30项；在国际著名外科学或肿瘤学期刊上发表SCI论文300余篇；获得发明专利10余项。参与国内几乎所有胰腺肿瘤诊治指南的撰写，并于2023年作为中国大陆唯一单位参与制定晚期胰腺癌诊治的国际专家共识。 作为国内最大的胰腺肿瘤综合诊治中心之一，中山胰腺外科每年完成胰腺切除手术超过1,200例，开展胰腺肿瘤综合诊治超过20,000人次，形成以“肝-胰联合切除（多器官联合手术）”、“转化后扩大根治（变不能开为可开）”、“微创手术（精准和保留器官功能）”以及“全周期管理”为主的学科特色。先后荣获上海市医学科技进步一等奖、二等奖，2022年度厦门市医疗十大创新技术等，是国内乃至国际领先的超大型胰腺肿瘤诊治中心。
查看欧洲杯买球官网 →论文：
1、Yin L, Pu N, Thompson E, Miao Y, Wolfgang C, Yu J. Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis. Clin Cancer Res. 2021 Feb 1;27(3):740-748. doi: 10.1158/1078-0432.CCR-20-1746. Epub 2020 Oct 20. PMID: 33082211.
2、Yin H, Pu N, Chen Q, Zhang J, Zhao G, Xu X, Wang D, Kuang T, Jin D, Lou W, Wu W. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic cancer. Cell Death Dis. 2021 Oct 30;12(11):1033. doi: 10.1038/s41419-021-04293-4. PMID: 34718325; PMCID: PMC8557215.
3、Xiang XS, Li PC, Wang WQ, Liu L. Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer. Biochim Biophys Acta Rev Cancer. 2022 Jan;1877(1):188676. doi: 10.1016/j.bbcan.2022.188676. Epub 2022 Jan 10. PMID: 35016922.
4、Xu ZH, Wang WQ, Liu L, Lou WH. A special subtype: Revealing the potential intervention and great value of KRAS wildtype pancreatic cancer. Biochim Biophys Acta Rev Cancer. 2022 Jul;1877(4):188751. doi: 10.1016/j.bbcan.2022.188751. Epub 2022 Jun 19. PMID: 35732240.
5、Chen Q, Yin H, Liu S, Shoucair S, Ding N, Ji Y, Zhang J, Wang D, Kuang T, Xu X, Yu J, Wu W, Pu N, Lou W. Prognostic value of tumor-associated N1/N2 neutrophil plasticity in patients following radical resection of pancreas ductal adenocarcinoma. J Immunother Cancer. 2022 Dec;10(12):e005798. doi: 10.1136/jitc-2022-005798. PMID: 36600557; PMCID: PMC9730407.
6、Chen Q, Yin H, He J, Xie Y, Wang W, Xu H, Zhang L, Shi C, Yu J, Wu W, Liu L, Pu N, Lou W. Tumor Microenvironment Responsive CD8+ T Cells and Myeloid-Derived Suppressor Cells to Trigger CD73 Inhibitor AB680-Based Synergistic Therapy for Pancreatic Cancer. Adv Sci (Weinh). 2023 Nov;10(33):e2302498. doi: 10.1002/advs.202302498. Epub 2023 Oct 22. PMID: 37867243; PMCID: PMC10667825.
7、An YF, Pu N, Jia JB, Wang WQ, Liu L. Therapeutic advances targeting tumor angiogenesis in pancreatic cancer: Current dilemmas and future directions. Biochim Biophys Acta Rev Cancer. 2023 Sep;1878(5):188958. doi: 10.1016/j.bbcan.2023.188958. Epub 2023 Jul 24. PMID: 37495194.
8、Pu N, Wu W, Liu S, Xie Y, Yin H, Chen Q, He T, Xu Z, Wang W, Yu J, Liu L, Lou W. Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: a retrospective cohort study. Int J Surg. 2023 Oct 1;109(10):3137-3146. doi: 10.1097/JS9.0000000000000589. PMID: 37418574; PMCID: PMC10583928.
9、Liu S, Wu W, Du Y, Yin H, Chen Q, Yu W, Wang W, Yu J, Liu L, Lou W, Pu N. The evolution and heterogeneity of neutrophils in cancers: origins, subsets, functions, orchestrations and clinical applications. Mol Cancer. 2023 Sep 7;22(1):148. doi: 10.1186/s12943-023-01843-6. PMID: 37679744; PMCID: PMC10483725.
10、Xu ZJ, Li JA, Cao ZY, Xu HX, Ying Y, Xu ZH, Liu RJ, Guo Y, Zhang ZX, Wang WQ, Liu L. Construction of S100 family members prognosis prediction model and analysis of immune microenvironment landscape at single-cell level in pancreatic adenocarcinoma: a tumor marker prognostic study. Int J Surg. 2024 Jun 1;110(6):3591-3605. doi: 10.1097/JS9.0000000000001293. PMID: 38498399; PMCID: PMC11175822.
11、Chen Q, Yin H, Jiang Z, He T, Xie Y, Mao W, Han J, Liu S, Lou W, Wu W, Habib JR, Yu J, Liu L, Pu N. Poor clinical outcomes and immunoevasive contexture in CD161+CD8+ T cells barren human pancreatic cancer. J Immunother Cancer. 2024 Mar 26;12(3):e008694. doi: 10.1136/jitc-2023-008694. PMID: 38531664; PMCID: PMC10966787.